Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes-Reference-Cited by-同舟云学术

Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes

Published:2021-04-23 Issue:8 Volume:29 Page:619-625
ISSN:1541-2016
Container-title:Applied Immunohistochemistry & Molecular Morphology
language:en
Short-container-title:

Author:

Hoffman-Censits Jean H.,Lombardo Kara A.,Parimi Vamsi,Kamanda Sonia,Choi Woonyoung,Hahn Noah M.,McConkey David J.,McGuire Bridget M.,Bivalacqua Trinity J.,Kates Max,Matoso Andres

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Medical Laboratory Technology,Histology,Pathology and Forensic Medicine

Reference26 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Emerging therapeutic targets in bladder cancer;Carneiro;Cancer Treat Rev,2015

3. Antibody-drug conjugates: present and future;Beck;Mabs,2014

4. Maturing antibody-drug conjugate pipeline hits 30;Mullard;Nat Rev Drug Discov,2013

5. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models;Challita-Eid;Cancer Res,2016

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series;Cancers;2024-09-01

2. A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection;International Cancer Conference Journal;2024-08-31

3. Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan;Cancers;2024-07-25

4. PD‐L1 and nectin‐4 expression and genomic characterization of bladder cancer with divergent differentiation;Cancer;2024-07-03

5. Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development;Cancers;2024-06-30